Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drug screening

Don't discount all curcumin trial data

We argue that the clinical potential of the spice extract curcumin should not be dismissed simply on the grounds that it yields confusing results in molecular drug screens (Nature 541, 144–145; 2017; see also K. M. Nelson et al. J. Med. Chem.; 2017).

Nelson and colleagues claim a lack of evidence for curcumin's therapeutic benefits “despite thousands of research papers and more than 120 clinical trials” ( However, a PubMed search under 'curcumin double-blind placebo-controlled clinical trial' yields 49 entries, of which 17 recent trials show efficacy. In addition, there are 27 other clinical trials and at least 5 animal studies of curcumin that point to therapeutic benefits (see full reference list in Supplementary information).

The assumption that a drug candidate must have a single known target and compatibility with high-throughput screening to enter the clinic can preclude promising drug candidates (R. L. Elliott Am. Chem. Soc. Med. Chem. Lett. 3, 688–690; 2012). Current detection methods for target engagement cannot gauge the full pharmacological spectrum of an investigational drug, so should be used with other screening paradigms. Also, the binding behaviour of curcumin to multiple molecular targets is associated with modulation rather than outright inhibition. And high-throughput screening is prone to technical artefacts that can make it a deceptive arbiter for excluding potential drugs.

In light of these considerations, curcumin's molecular targets and their regulatory mechanisms warrant further investigation if we are to build on the promising results that are already to hand in humans and animals.

Author information



Corresponding author

Correspondence to Michal Heger.

Supplementary information

Related links

Related links

Related links in Nature Research

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Heger, M. Don't discount all curcumin trial data. Nature 543, 40 (2017).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing